{
    "clinical_study": {
        "@rank": "9851", 
        "acronym": "URIC", 
        "arm_group": [
            {
                "arm_group_label": "Gouty arthritis", 
                "description": "Patient with gouty arthritis"
            }, 
            {
                "arm_group_label": "Asymptomatic hyperuricemia", 
                "description": "Patient with asymptomatic hyperuricemia"
            }, 
            {
                "arm_group_label": "OA without hyperuricemia", 
                "description": "Patient of osteoarthritis but without hyperuricemia and gout"
            }
        ], 
        "biospec_descr": {
            "textblock": "serum"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease,\n      but the exact mechanism remained to be elucidated. Many connective tissue diseases such as\n      rheumatoid arthritis are often associated with antiphospholipid antibodies-associated\n      endothelial impairment. In the present study, the investigators will analyze the presence of\n      antiphospholipid antibodies in the serum of the patients with gout/asymptomatic\n      hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia\n      and gout. The investigators expect to find a correlation between these pathogenic antibody\n      and those cardiovascular co-morbidities."
        }, 
        "brief_title": "The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome", 
        "condition": [
            "Antiphospholipid Syndrome", 
            "Endothelial Dysfunction", 
            "Hyperuricemia", 
            "Gout", 
            "Metabolic Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Gout", 
                "Antiphospholipid Syndrome", 
                "Metabolic Syndrome X", 
                "Hyperuricemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease,\n      but the exact mechanism remained to be elucidated. Many connective tissue diseases such as\n      rheumatoid arthritis are often associated with antiphospholipid antibodies-associated\n      endothelial impairment. In the present study, we'll analyze the presence of antiphospholipid\n      antibodies in the serum of the patients with gout/ asymptomatic hyperuricemia, with a\n      comparison to the patients of osteoarthritis but without hyperuricemia and gout. We expect\n      to find a correlation between these pathogenic antibody and those cardiovascular\n      co-morbidities.\n\n      Patient eligibility\uff1a\n\n        1. Patients with gout\n\n        2. Patients with asymptomatic hyperuricemia\n\n        3. Patients of osteoarthritis but without hyperuricemia and gout Exclusion Criteria\uff1a\n           Patients younger than 20 years old"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient with gouty arthritis\n\n          2. Patient with asymptomatic  hyperurecemia\n\n          3. Patient of osteoarthritis but without hyperuricemia and gout\n\n        Exclusion Criteria:\n\n        1.Patient younger than 20 y/o."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "General population"
            }
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818505", 
            "org_study_id": "URIC"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Antiphospholipid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "antiphospholipid syndrome", 
            "gouty arthritis", 
            "Hyperuricemia", 
            "metabolic syndrome", 
            "osteoarthritis", 
            "cardiovascular co-morbidities"
        ], 
        "lastchanged_date": "April 11, 2014", 
        "location": {
            "contact": {
                "email": "543goole@gmail.com", 
                "last_name": "Yu-Minn Kuo, MD", 
                "phone": "8655323911", 
                "phone_ext": "5826"
            }, 
            "facility": {
                "address": {
                    "city": "Dou-Liou City", 
                    "country": "Taiwan", 
                    "state": "Yun-Lin County", 
                    "zip": "640"
                }, 
                "name": "National Taiwan University Hospital Yun-Lin Branch"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_groups": "3", 
        "official_title": "The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome", 
        "overall_contact": {
            "email": "543goole@gmail.com", 
            "last_name": "Yu-Min Kuo, M.D.", 
            "phone": "886972655701"
        }, 
        "overall_official": {
            "affiliation": "National Taiwan University Hospital", 
            "last_name": "Yu-Min Kuo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "development of metabolic syndrome or cardiovascular events", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818505"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Acute myocardial infarct or stroke", 
            "safety_issue": "No", 
            "time_frame": "36 months or more"
        }, 
        "source": "National Taiwan University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Taiwan University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}